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Objectives. This study sought to evaluate treatment of early 
intracoronary stent thrombosis. 
Background. Although refinements in intracoronary stent im- 
plantation technique and pharmacologic treatment have reduced 
the frequency of early stent thrombosis, stent thrombosis remains 
a feared complication of this procedure. Optimal treatment for 
stent thrombosis is still undefined. 
Methods. Twenty-nine patients (44 stents) with early (<30 
days) coronary stent thrombosis over a 5-year period at our 
institution were identified. Treatment and outcome of stent 
thrombosis were analyzed. 
Results. Mean (_+SD) time from implantation to stent throm- 
bosis was 6.1 + 5 days. Twenty-three patients were treated with 
catheter-based therapies (angioplasty alone in 14, angioplasty and 
intracoronary urokinase in 7, intracoronary urokinase alone in 2). 
Flow was restored without residual thrombus in 11 (48%) of the 
catheter-treated patients (6 of 14 with angioplasty alone, 4 of 7 
with angioplasty and urokinase, 1 with urokinase alone). Of the 23 
patients, 2 died despite restoration of anterograde flow, and 9 
were referred for emergent or urgent bypass surgery because of 
residual thrombus and refractory angina despite restoration of 
blood flow. Of the remaining six patients, five were treated 
medically and one with coronary bypass surgery; three died. Acute 
myocardial infarction evolved in 26 patients (90%), including 20 
(87%) of the 23 catheter-treated patients. 
Conclusions. Stent thrombosis is associated with severe adverse 
outcomes. Although catheter-based therapies are effective in re- 
storing patency in a majority of patients, patients are referred 
frequently for coronary bypass surgery because of residual throm- 
bus and refractory angina. These findings suggest hat alternative 
or adjunctive therapies for stent thrombosis are needed. 
(J Am Coll Cardiol 1996;28:361-7) 
Intracoronary stents have become an important addition to the 
current practice of angioplasty. The most feared complication 
related to stent placement is early stent hrombosis, which has 
occurred in the past with a frequency of up to 12% (1-5). As 
a result of recent refinements in stent implantation technique 
and postprocedural pharmacologic treatment, the incidence of 
stent thrombosis after implantation of coronary stents is 
reported to be lower (6) than the rate of 3.5% reported in the 
two initial randomized studies comparing coronary angioplasty 
and stent placement inelective de novo lesions (7,8). Although 
previous studies have characterized the patients at risk for 
stent thrombosis (1-5), there are few data pertaining to the 
optimal therapeutic approach to stent thrombosis. Catheter- 
based therapies for stent hrombosis are applied frequently in
clinical practice (2,3,5,9), yet their efficacy has not been 
evaluated in a large group of patients. We thus examined the 
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therapeutic approaches and clinical course of all patients with 
early stent hrombosis at our institution over a 5-year period. 
Methods  
Study protocol. The study protocol was approved by the 
Mayo Clinic Institutional Review Board. We performed a
retrospective analysis of the Mayo Clinic coronary intervention 
data base, obtaining data pertaining to all patients who had 
stents placed with a follow-up period of at least 6 months after 
the procedure. Of all patients who had intracoronary stents 
placed between January 1990 and June 1995, we scrutinized 
the records of those who had repeat angiography, intervention, 
coronary bypass urgery, acute myocardial infarction or death 
within 30 days of stent implantation. Early stent thrombosis 
was defined clinically as the sudden onset of chest pain 
associated with electrocardiographic (ECG) changes in the 
distribution of the target vessel suggestive ofacute ischemia or 
infarction, occurring within 30 days of stent placement. In 
patients in whom coronary angiography was performed, stent 
thrombosis was confirmed if there was occlusion (Thromboly- 
sis in Myocardial Infarction [TIMI] flow grade 0 or 1) within 
the stent with angiographic evidence consistent with thrombus 
(discrete occlusive intraluminal filling defect of convex curva- 
ture within or adjacent to the stenotic region [2,10]). Definite 
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diagnosis of thrombus was made if there was one or more 
lumen filling defects in the absence of a major dissection (10). 
Probable diagnosis of thrombus was made if there were lumen 
filling defects with minor dissection (linear extraluminal cap in 
orthogonal views without lumen compromise) (10) or if the 
lumen appeared to be hazy in orthogonal views. Abrupt 
closure after coronary angioplasty or stent placement may 
result from coronary artery dissection or formation of intra- 
coronary thrombus, or both (11). In our study, we excluded 
patients in whom it was believed that the primary mechanism 
for abrupt closure after stent placement was significant coro- 
nary artery dissection remote from the stent site, without 
definite evidence of thrombus within the stent (10). 
Medical records of all patients who had early stent throm- 
bosis after stent implantation were reviewed. The records of 
patients who were admitted to the hospital for stent hrombo- 
sis at outside medical institutions were also obtained and 
analyzed. Angiographic data acquired uring stent placement 
were reviewed, including target vessel, extent of coronary 
artery disease (defined as the number of major epicardial 
arteries with ---50% diameter stenosis in addition to >-70% 
diameter stenosis of the target vessel; patients with >-50% 
stenosis of the left main coronary artery were considered to 
have two-vessel disease with right-dominant systems and three- 
vessel disease in the case of left-dominant systems), percent 
diameter stenosis before and after stent deployment (visual 
assessment), TIMI flow grade after stent placement and pres- 
ence of dissection (filling defect within vessel wall [2,10]) or 
thrombus during the procedure. Indications for stent deploy- 
ment were categorized as either elective (for recurrent resten- 
osis or complexity of lesion), treatment of abrupt closure after 
coronary angioplasty (worsening stenosis with TIMI grade 0 or 
1 flow [2,10,11]) or suboptimal angioplasty result (with or 
without dissection). International normalized ratio (INR) of 
prothrombin time values for patients receiving warfarin and 
activated partial thromboplastin time values for patients re- 
ceiving heparin were documented atthe time of stent throm- 
bosis. 
For all patients, the therapeutic strategy used for stent 
thrombosis and the clinical outcome (evolution of myocardial 
infarction, referral for urgent or emergent coronary artery 
bypass graft surgery or death) were noted. Acute myocardial 
infarction was defined when at least two of the following three 
criteria were met (12): 1) chest pain >30 rain, 2) persistent 
ECG changes, or 3) characteristic elevations in serum creatine 
kinase (CK) levels with a corresponding increase in MB 
isoform. In patients treated with catheter-based therapies 
(angioplasty; angioplasty and intracoronary thrombolysis; or 
intracoronary thrombolysis alone), percent diameter stenosis 
before and after the intervention, postprocedural TIMI grade 
flow and presence of residual thrombus were noted. 
Angioplasty technique for stent implantation. All angio- 
plasty procedures were performed using standard techniques 
(13) through the femoral artery. Intracoronary stent implanta- 
tion techniques evolved over the study period. Gianturco- 
Roubin (Cook Inc.) and Wiktor (Medtronic Inc.) stents were 
generally placed across target lesions using 0.046-cm 
(0.018-in.) extra support guide wires for delivery, as described 
previously (14,15). Coronary and biliary Palmaz-Schatz stents 
(SDS, Johnson & Johnson Interventional Systems) were posi- 
tioned within the delivery sheath or on the balloon catheter, 
respectively, over 0.036-cm (0.014-in.) extra support guide 
wires (followed by retraction of the sheath in the case of 
coronary stents) (16). Delivery balloons were inflated to nom- 
inal pressure. As of 1994, stent delivery has been routinely 
followed by high pressure (>-14 atm) balloon inflations using 
noncompliant or minimally compliant balloons at sizes equiv- 
alent to or slightly larger than nominal stent size to achieve 
residual diameter stenosis <20% without intraluminal filling 
defects. Intravascular ultrasound was used to evaluate stent 
deployment at the discretion of the operator. 
All patients received preprocedural oral aspirin (325 rag) 
and received intraprocedural heparin to achieve an activated 
clotting time >300 s. Until 1994, patients received dextran 
immediately before the procedure in accordance with the stent 
manufacturer's instructions. Our protocol for stent implanta- 
tion until late 1994 included warfarin (target INR of 2.0 to 4.0), 
aspirin (81 to 325 mg once daily) and dipyridamole (75 mg 
three times daily). As of late 1994, warfarin was administered 
only to patients with suboptimal stent deployment as assessed 
by coronary angiography or intravascular ultrasound or with an 
unfavorable clinical profile. Otherwise, patients were treated 
indefinitely with aspirin (81 to 325 mg once daily) and ticlopi- 
dine (250 mg twice daily) for 4 to 6 weeks. 
Angioplasty technique for stent thrombosis. Patients with 
suspected early stent thrombosis were taken immediately to 
the catheterization laboratory, and angiography was per- 
formed using standard percutaneous techniques through the 
femoral artery or cutdown of the brachial artery. Once stent 
thrombosis was confirmed and a decision was made to proceed 
with angioplasty with or without intracoronary thrombolytic 
therapy at the discretion of the operator, the occlusion was 
generally crossed with a soft/floppy guide wire, ensuring that 
the wire passed freely through the stent lumen. The guide wire 
was shaped to have an exaggerated "J" or "C" curve at its tip 
to facilitate passage through the occluded stent. Once the 
guide wire was passed istally, over-the-wire t chniques were 
used and balloon catheters were advanced and inflated at the 
occlusion site. Balloon sizes were selected to achieve residual 
diameter stenosis <20% without intraluminal filling defects. 
Specific balloon size selection and inflation pressures were at 
the discretion of the operator. When intracoronary urokinase 
was administered, the drug was delivered through the guiding 
catheter or through the angioplasty catheter or drug-infusion 
catheter. 
Statistics. Comparison of patients who subsequently devel- 
oped early stent thrombosis with those who did not was 
performed using the Student -test for continuation variables 
and the chi-square test for discrete variables; p values --0.05 
were considered significant. 
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Table 1. Demographic, Clinical and Angiographic Profile of Study 
Patients With Intracoronary Stents With and Without Early 
Stent Thrombosis 
Stent No Stent 
Thrombosis Thrombosis p 
(n = 29) (n = 732) Value 
Age (yr) 58 -+ 14 63 2 11 0.05 
Male 21 (72%) 540 (74%) NS 
Unstable angina 23 (79%) 569 (78%) NS 
Previous myocardial nfarction 23 (79%) 388 (53%) 0.01 
Diabetes mellitus 5 (17%) 140 (19%) NS 
Hypertension 13 (45%) 408 (56%) NS 
Hypercholesterolemia 9 (31%) 379 (52%) 0.05 
Smoking 
Current 11 (38%) 112 (15%) 0.001 
Former 14 (48%) 355 (49%) NS 
Previous coronary bypass surgery 5 (17%) 241 (33%) NS 
Extent of coronary artery disease NS 
One vessel 10 (34.5%) 238 (32.5%) 
Two vessels 9 (31%) 293 (40%) 
Three vessels 10 (34.5%) 201 (27.5%) 
Data presented are mean value _+ SD or number (%) of patients. 
Results  
Study cohort. Of 761 consecutive patients in whom intra- 
coronary stents had been implanted, 29 with early thrombotic 
occlusion of coronary artery stents were identified (3.8%). 
Follow-up was complete for all patients who received intra- 
coronary stents. The demographic and clinical profile of the 
patient cohort is presented in Table 1. Compared with patients 
who received intracoronary stents but without subsequent 
early stent thrombosis, patients with early stent thrombosis 
were younger, had a higher incidence of smoking, had a higher 
rate of previous myocardial infarction and had lower choles- 
terol levels. In all, 44 stents had been placed in patients with 
early stent thrombosis (one stent in 18, two stents in 8, three 
stents in 2, four stents in 1). Thirty-three Gianturco-Roubin 
stents were placed in 23 patients, seven Palmaz-Schatz stents 
were placed in 5 patients, and four Wiktor stents were placed 
in 2 patients. One patient received one Palmaz-Schatz and one 
Gianturco-Roubin stent. Stent thrombosis occurred 6.1 _ 5 
days (mean _+ SD, range 0 to 20) after stent implantation; stent 
thrombosis occurred within 24 h (early) in 4 patients and 
between 1 and 30 days after stent placement (subacute) in 25. 
Angiographic onfirmation of stent thrombosis was available 
for 27 patients (93%). 
Stent placement and pharmacologic therapy. Indications 
for stent placement are presented in Table 2. Seven patients 
had stents placed for acute myocardial infarction. Table 3 
describes the distribution of treated vessels. One patient had 
stents placed in both the left anterior descending and left 
circumflex coronary arteries. Mean nominal balloon and stent 
sizes were 3.3 _+ 0.4 and 3.2 _+ 0.4 mm (range 2.5 to 4), 
respectively. Mean vessel diameter stenosis was 54 __ 23% 
after predilation with a balloon catheter and before stent 
placement and 10 _ 11% after stcnt placement. Intraluminal 
Table 2. Indications for Initial Stent Placement for Entire Group 
and for Subgroup of Patients With Stents Placed in Setting of Acute 
Myocardial Infarction 
Indication No. of Patients 
All patients 
Elective 5 
Abrupt closure after angioplasty 2 
Suboptimal ngioplasty 22 
Total 29 
Patients with stents placed in setting of acute 
myocardial nfarction 
Abrupt closure after angioplasty 2 
Dissection after angioplasty 1 
Adjunctive therapy for suboptimal direct angioplasty 3 
Rescue angioplasty after failed thrombolytic therapy 1 
Total 7 
filling defects consistent with thrombus were evident angio- 
graphically before stent placement in 14 (48%) of 29 patients; 
the angiographic diagnosis of thrombus was graded as proba- 
ble in 5 patients and as definite in 9. Coronary artery dissection 
was evident angiographically in eight patients (28%); in two 
patients the dissection was external to the stent, and in the 
remaining six patients there were mild to moderate residual 
dissections distal to the segment receiving the stent. High 
pressure balloon inflations were performed uring initial stent 
placement in 11 (38%) of 29 patients. Intravascular ultrasound 
or coronary angioscopy was used to evaluate the success of 
stent deployment in four and one patients, respectively; TIMI 
grade 3 flow was evident in all patients at the end of the 
procedure. After receiving intravenous heparin during the 
procedure (target activated clotting time >300 s), patients 
were maintained on anticoagulant and antithrombotic agents 
as deemed necessary by the attending physician. A detailed 
account of anticoagulant and antithrombotic therapy on pre- 
sentation with stent hrombosis provided in Table 4. Twenty- 
five patients (86%) were receiving warfarin, 27 (93%) aspirin, 
16 (55%) heparin, 12 (41%) dipyridamole, and 2 (7%) ticlo- 
pidine. Measurements of the INR on presentation with stent 
thrombosis were available in 21 of the 25 patients treated with 
warfarin. Nine patients had INR values ->2. The remaining 12 
patients had INR values <2, but 8 of these were receiving 
adequate anticoagulant medication with heparin (activated 
partial thromboplastin time >70 s). 
Stent thrombosis. Five of the 29 patients died after stent 
thrombosis, and 26 had an acute myocardial infarction. Treat- 
Table 3. Distribution of Target Vessels in Which Stents 
Were Placed 
Target Vessel No. of Patients 
Left anterior descending coronary artery 16 
Left circumflex coronary artery 6 
Right coronary artery 6 
Saphenous venous bypass graft* 2 
*To left anterior descending and right coronary arteries. 
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Table 4. Anticoagulant d Antithrombotic Therapy in Patients 
Presenting With Stent Thrombosis 
No. of 
Heparin Aspirin Warfarin Ticlopidine Dipyridamole Patients 
+ + + + + 1 
+ + + + 5 
+ + + 8 
+ + 1 
+ 2 
+ + + 5 
+ + 1 
+ + 4 
+ 1 
+ + + 1 
Total 29 
*See text for specific doses. 
ment strategies and their specific outcomes are described in 
the following sections. 
Non-catheter-based treatment. Five patients were treated 
medically (with antianginal therapy but no thrombolytic 
agents), four because of severe, comorbid underlying disease 
and one because the area at risk was assessed to be small. Two 
of these patients died within 17 and 30 days after a protracted 
and complicated hospital period. One additional patient was 
sent directly to emergency coronary bypass surgery after 
coronary angiography had confirmed stent thrombosis and 
placement of intraaortic balloon pump but died shortly after 
operation. 
Catheter-based therapies. The remaining 23 patients were 
treated with catheter-based therapies (Fig. 1). Mean vessel 
diameter stenosis in these patients was improved from 98 _+ 
7% to 35 _+ 34%. Mean nominal balloon size at stent deploy- 
ment and during treatment for the stent hrombosis was similar 
(3.3 ___ 0.4 mm at stent deployment vs. 3.4 ~ 0.4 mm for stent 
thrombosis). High pressure balloon inflations were performed 
during angioplasty in one patient for treatment of stent 
thrombosis, and in two patients after stent deployment during 
treatment of stent hrombosis. Intracoronary urokinase doses 
varied. Among five patients treated with angioplasty and 
urokinase, a bolus of 250,000 U (three patients) or 500,000 U
(two patients) was delivered over 10 to 20 min. Two additional 
patients received prolonged intracoronary infusions of uroki- 
nase (for -12 h) at a rate of 100,000 U/h (after a bolus of 
250,000 U in one patient). Both patients who were treated with 
intracoronary urokinase alone (i.e., without angioplasty) re- 
ceived a total of 250,000 U over 10 to 20 min. 
In 11 (48%) of 23 patients, TIMI grade 3 flow was achieved 
without evidence of residual stent thrombosis (6 of 14 with 
angioplasty alone, 4 of 7 with angioplasty combined with 
intracoronary urokinase, 1 with intracoronary urokinase 
alone). Anterograde flow could not be restored in two patients 
treated with angioplasty alone; one was managed medically, 
and the other was referred immediately for emergency oro- 
nary bypass urgery. Nine (43%) of 21 patients treated with 
angioplasty (3 with adjunctive intracoronary urokinase infu- 
sion) were referred for emergent or urgent coronary bypass 
surgery (mean 2 + 3.9 days, median 1) because of the presence 
of residual thrombus and continuing angina despite restoration 
of normal anterograde blood flow. Four of these nine patients 
were sent immediately from the catheterization laboratory to 
bypass urgery, three were sent within 24 h, and the remaining 
two patients 3 and 12 days after angioplasty (six patients had 
lesions in the left anterior descending coronary artery, two in 
the left circumflex coronary artery and one in the right 
coronary artery). Additional stents (one Palmaz-Schatz and 
one Gianturco-Roubin) were placed in two patients treated 
with angioplasty and intracoronary urokinase; one was referred 
for emergent coronary bypass surgery because of residual 
Catheter-Based Therapies 
23 
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Figure I. Flow diagram summarizing the manage- 
ment and angiographic and clinical outcome of pa- 
tients with early stent thrombosis treated with 
catheter-based trategies. TIMI = Thrombolysis in 
Myocardial Infarction. 
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Figure 2. Photomicrographs of thrombus within an 
intracoronary stent taken from a patient who died after 
treatment with angioplasty and intracoronary uroki- 
nase for early stent thrombosis. A, Platelet-rich t rom- 
bus (solid arrow) within a section of the left anterior 
descending coronary artery. Note the indentations of 
the Gianturco-Roubin stent (open arrows) apposed to
the vessel wall. Elastic-van Gieson stain X 35, reduced 
by 35%. B, Hematoxylin a d eosin stain of thrombus 
within stent in left anterior descending coronary ar- 
tery. Note the abundance of platelets ( olid arrows) 
interwoven within fibrin strands that form the throm- 
bus. Leukocytes (open arrows) are seen at the margins 
of recanalized channels within the thrombus, x295, 
reduced by 35%. 
thrombus, and the other recovered uneventfully. Acute myo- 
cardial infarction evolved in 20 (87%) of the 23 patients 
treated with catheter-based therapies, with a mean peak serum 
CK value of 1,928 _+ 1,610 U/liter. 
Two patients died 11 and 15 days after catheter-based treat- 
ment of stent thrombosis, although TIMI grade 3 anterograde 
flow had been restored. One of these had received intracoronary 
uroldnase infusion alone (bolus of 250,000 U), and another had 
been treated with angioplasty and intracoronary urokinase infu- 
sion (bolus of 250,000 U followed by infusion of 100,000 U/h for 
12 h). Autopsy in the latter patient revealed acute platelet-fibrin 
thrombotic occlusion of stent sites with platelet-fibrin emboli 
within small intramural coronary arteries, resulting in spotty 
transmural cute myocardial infarction (Fig. 2). 
Discuss ion  
The results of our study are in accord with previous data 
demonstrating that early stent hrombosis i  associated with a 
poor clinical outcome; 26 of 29 patients had an acute myocar- 
dial infarction, and 5 died. Moreover, catheter-based therapies 
for stent hrombosis were found to be only modestly effective 
in the treatment of early stent thrombosis. Although TIMI 
grade 3 flow was restored in 21 of 23 patients treated with 
catheter-based therapies, 20 of these patients developed an 
acute myocardial infarction (87%), and 9 were referred for 
urgent or emergent coronary bypass urgery because of resid- 
ual thrombus threatening reclosure of the treated vessel. Of 
the 11 patients who underwent coronary bypass urgery (of 
whom 10 were treated with prior catheter-based therapies), 
1 died. 
Previous studies. Most available data regarding manage- 
ment of early stent thrombosis are derived from reports 
describing experience with a single stent design and from 
relatively small numbers of patients. Nath et al. (2) reported 
that among 145 patients who underwent Gianturco-Roubin 
stent placement for abrupt vessel closure or for prevention of 
restenosis, 17 (11.7%) had thrombotic closures. Intracoronary 
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thrombolytic therapy was administered, and repeat coronary 
balloon dilation was performed in all patients. Successful 
recanalization was achieved in only 7 patients (41%); 13 had an 
acute myocardial infarction, and 8 were referred for coronary 
bypass urgery. Foley et al. (5) reported their experience with 
Palmaz-Schatz stent implantation i  160 consecutive patients: 
Stent thrombosis occurred in 12 patients (7.5%), 10 of whom 
were treated with angioplasty with or without intracoronary 
thrombolytics. Patency was restored in 50% of patients treated 
with angioplasty. Haude et al. (3) described 100 consecutive 
patients with intracoronary implantation of 118 Palmaz-Schatz 
stents, 10 (10%) of whom developed subacute stent hrombo- 
sis. In contrast to the previously described studies, eight of the 
nine patients managed with catheter-based therapies had flow 
restored. The discrepancies in outcome among the different 
studies could possibly be explained in part by patient 
selection, stent type, indication for stenting, operator expe- 
rience and perhaps the use or nonuse of intracoronary 
thrombolytic therapy. However, common to all these studies 
is a high rate of severe adverse clinical outcomes despite 
revascularization attempts. 
Thrombus. Primary angioplasty has been advocated by 
some as the therapy of choice for acute myocardial infarction 
because of high success rates and improved clinical outcomes 
compared with thrombolytic therapy (17,18). Because intra- 
coronary thrombus is common to acute myocardial infarction 
and stent thrombosis, it is of interest hat angioplasty appears 
to be of much lower efficacy in restoring flow and resolving 
residual thrombus in the latter condition. Our data, as well as 
previous data (2,5), indicate that thrombolytic therapy adjunc- 
tive to angioplasty is of limited efficacy in resolving residual 
thrombus formation within the stent site and possibly could 
even be harmful. In fact, Ambrose t al. (10) recently reported 
that adjunctive intracoronary urokinase during angioplasty of 
thrombus-containing lesions in patients with unstable angina is 
associated with adverse angiographic and clinical events, per- 
haps because of platelet-activating effects of urokinase. One 
can only speculate as to the different mechanisms for thrombus 
formation in these two situations and how this affects treat- 
ment with thrombolytic agents. It is possible that even higher 
doses or prolonged infusions of thrombolytic agents might be 
more effective for treatment of stent thrombosis, as reported 
for treatment of occluded venous grafts (19,20), but this could 
also be associated with a significantly higher complication rate, 
and substantially prolonged instrumentation of the vessel 
containing a stent is probably best avoided to prevent further 
complications. Alternatively, it is possible that the thrombus 
that forms within the intracoronary stent is resistant to throm- 
bolytic agents. 
Analysis of the thrombus composition i  a porcine experi- 
mental model of stent thrombosis has revealed that it is 
platelet-rich in content (21). Indeed, a postmortem study of 
one of our patients who died after treatment with angioplasty 
and intracoronary urokinase infusion revealed acute platelet- 
fibrin thrombotic occlusion of stent sites with platelet-fibrin 
emboli within small intramural coronary arteries (Fig. 2). 
Because thrombolytic agents exert their effect primarily by 
fibrinolysis, they may be expected to have limited efficacy in 
resolving platelet-rich thrombi (22). Moreover, the efficacy of 
thrombolytic agents may be blunted by the high content of 
plasminogen activator inhibitor in these thrombi (23). It re- 
mains to be determined whether alternative adjunctive 
antiplatelet agents such as platelet glycoprotein IIb/IIIa 
receptor antagonists or antithrombin agents uch as hirudin 
can improve clinical outcome among patients with early 
stent thrombosis. 
The great majority of patients with stent hrombosis n our 
series were receiving warfarin at the time of stent occlusion. 
Most of these patients were well anticoagulated, with INR 
values >2, or were receiving concomitant infusion of heparin 
with adequate activated partial thromboplastin time values 
(>70 s). Thus, it is apparent hat adequate anticoagulation 
with warfarin does not prevent he occurrence of early stent 
thrombosis. Indeed, warfarin may promote a procoagulant 
state because of its initial inhibitory effects on the anticoagu- 
lants proteins C and S, as implicated in other thrombotic 
diatheses (24). However, the potential contribution of war- 
farin to the thrombotic episodes in stent recipients remains 
speculative. 
In our series of patients, we observed a relatively high rate 
of referral for coronary bypass urgery despite restoration of 
anterograde flow. These patients had angiographic evidence of 
residual thrombus and experienced refractory angina. There 
are few other data regarding the outcomes of patients with 
stent thrombosis and restored flow with residual thrombus. 
Although all patients in our study referred for urgent or 
emergent coronary bypass urgery after angioplasty because of 
residual thrombus fared well, it is possible that medical therapy 
may have also been successful. 
Study limitations. The present study was a retrospective 
analysis of different stent types and different echnical ap- 
proaches to stent deployment. Follow-up of patients receiving 
intracoronary stents in our institution was complete, and 
although it is unlikely that symptomatic events were missed, we 
cannot exclude the possibility that silent stent thrombosis 
might have been missed. In addition, because of the small 
number of patients receiving a particular therapeutic modality, 
and because the choice of the therapeutic approach was at the 
discretion of the operator, it is not possible to assess differ- 
ences in outcome with different herapeutic approaches. It
should also be emphasized that it was not the goal of this study 
to describe predictors of early stent hrombosis occurrence but 
rather to provide insight into the clinical course of patients 
with stent thrombosis and evaluate the efficacy of commonly 
used therapeutic strategies. Last, high pressure balloon infla- 
tions were not routinely performed uring treatment of stent 
thrombosis. It is possible that higher inflation pressures, per- 
haps with larger balloons, and verification of adequate stent 
apposition with intravascular ultrasound might have resulted in 
better esolution of residual thrombus. 
Conclusions. Initial experience with intracoronary stents 
resulted in relatively high complication rates (1-5), which 
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improved dramatically over time with improved technical 
expertise, patient selection and adjunctive therapy (6). How- 
ever, as more experience with stent implantation is gained, 
patients with increasingly complex clinical and angiographic 
profiles may be treated. In addition, the use of stents in 
interventional cardiology practice worldwide continues to 
grow rapidly. Thus, the rate of stent thrombosis may actually 
increase over time, and the absolute number of cases even 
more so. 
In our series of patients treated with coronary stent place- 
ment, early stent thrombosis was associated with high rates of 
adverse clinical outcomes. Catheter-based therapies were suc- 
cessful in restoring normal flow but were of modest efficacy in 
the management of these patients because of the high inci- 
dence of associated adverse clinical events. It is therefore 
imperative to formulate more effective treatment strategies for 
early stent thrombosis. 
We thank LaVonne Hammes for invaluable help with data collection. 
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